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ABSTRACT
Background UK primary care records are com-
puterised and these records are used for both research
and quality improvement. However, there is dis-
parity in the prevalence of diabetes found in epi-
demiological studies compared with that reported
through the UK’s national quality improvement
scheme.
Objective To investigate how non-diagnostic com-
puter data could be used to identify, conﬁrm or
refute prevalent cases of people with diabetes.
Method We carried out a literature review to
identify the most accurate non-diagnostic markers.
For each type of diabetes we focused on four broad
areas; demographic details, biochemical markers,
clinical features and therapeutic strategies. Sample
markers were tested by calculating their positive
predictive value (PPV) and sensitivity (Sn) and their
ability to diﬀerentiate between types of diabetes.
Results Biochemical markers were useful in iden-
tifying cases of diabetes but not in diﬀerentiating
between types of diabetes as the same plasma
glucose criterion is used to diagnose Type 1, Type 2,
and ‘other’ types of diabetes; the lack of a ‘fasting’
qualiﬁer blunts the use of this marker.
Auto-immunemarkerswere themost accurate in
identifying Type 1 diabetes but are not recorded
frequently in primary care.
Clinical features of diabetes and therapeutic
strategies were of some use – however, without
time sequence data are diﬃcult to interpret.
Raised plasma glucose (PG), and glycated haemo-
globin (HbA1c), had useful PPV but low Sn. When
PG was more than 7.0 and less than 11.1 mmol/l,
PPV equalled 77.8% and Sn 48%; and when PGwas
11.1, PPV equalled 92% and Sn 17%. For anHbA1c
of more than 6.5%, PPV was 89% and Sn 73.3%,
and for anHbA1c ofmore than 8, PPVwas 92%and
Sn 26%.
A person with a combination of aged under 30
years and prescribed insulin has an 84% PPV of
Type 1 diabetes; if they also have a BMI <30 kg/m2
the PPV increases to 88%. A person age over 45
years and with a BMI >30 kg/m2 has a 5.3% PPV of
Type 2 diabetes; if they are also hypertensive the
PPV is 30%; Asian ethnicity increases PPV to 44%.
Conclusion Non-diagnostic data has the potential
to conﬁrm or refute the diagnosis of diabetes and
identify its type.
Keywords: algorithms, computer systems, diabetes
mellitus, family practice, medical informatics,
medical record systems, computerised, vocabulary,
controlled
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Introduction
Diabetes mellitus is one of the greatest health chal-
lenges facing the UK, with an estimated prevalence of
approximately 4%.1,2 However, according to data from
the Quality and Outcomes Framework (QOF; ﬁnan-
cially incentivised quality targets), the prevalence of
diabetes is 3.7% (NHS Information Centre).3
Many diﬀerent diagnostic labels have been used to
classify diabetes: the terms insulin dependent diabetes
mellitus (IDDM) and non-insulin dependent diabetes
mellitus (NIDDM) were used by the World Health
Organization (WHO) in 1985.3 This was updated in
1999,when theNIDDMand IDDMtermswere dropped
and a new classiﬁcation introduced (Table 1).
The majority of UK general practices are com-
puterised and key data coded as recommended by
the Royal College of General Practitioners and the
British Medical Association. This rich pool of data
provides an opportunity to use non-diagnostic com-
puter codes not only to identify unrecorded cases of
diabetes but also to classify the type of diabetes
according to the WHO 1999 classiﬁcation.
This paper reports the feasibility of creating algor-
ithms able to conﬁrm or refute both the diagnosis of
diabetes and the type of diabetes.
Method
We conducted a literature review using Medline to
identify articles about the diagnosis of diabetes. The
literature review focused on three main areas. We ﬁrst
looked at biochemical markers such as fasting plasma
glucose (FPG) and oral glucose tolerance tests (OGTT)
since these are the foundation of accurate diagnostic
testing of diabetes. Clinical features and associated
conditions were another area that identiﬁed various
risk factors such as age, BMI, ethnicity etc. which are
linked to speciﬁc types of diabetes. The therapeutic
strategies currently employed in diabetes care were
also investigated.
Putative algorithms were then generated using the
following surrogate biochemical, clinical and thera-
peutic markers; age, insulin prescription, anti-obesity
prescription, BMI, polyuria, plasma glucose level and
plasma HbA1c level. Speciﬁcity (Sn) and Positive
Predictive Value (PPV) analysis was performed to assess
whether the algorithm, generated on the basis of surro-
gate markers, was robust in identifying diagnosed
cases of diabetes from a known dataset.
Table 1 WHO Classiﬁcation of Diabetes
Category Description
Type 1 -cell destruction, usually leading to absolute insulin deﬁciency
auto-immune
idiopathic
Type 2 May range from predominantly insulin resistant with relative insulin
deﬁciency to a secretory defect with or without insulin resistance
Other speciﬁc types
Genetic Genetic forms of diabetes sometimes described as MODY (maturity
onset diabetes of the young)
Drug or chemical induced E.g. secondary to steroid use
Unknown Individuals who do not clearly ﬁt into any of the above categories of
diabetes at the time of diagnosis
Gestational Glucose intolerance with ﬁrst onset or recognition during pregnancy.
If abnormal blood glucose levels persist after parturition the patient
must be reclassiﬁed under Type 1, Type 2, single gene or other
Not strictly diabetes
Impaired glucose metabolism Not strictly a type of diabetes. Plasma glucose levels are raised
insuﬃciently for a diagnosis of diabetes but are still above normal
range. Consists of two conditions:
IGT (impaired glucose tolerance)
IFG (impaired fasting glycemia)
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Results
Type 1 diabetes mellitus (T1DM)
Biochemical markers
Plasma glucose level testing is the gold standard in
diabetes diagnosis and is based on the WHO criteria:
. random venous plasma glucose = 11.1 mmol/l or
. fasting plasma glucose (no caloric intake for at least
eight hours) = 7.0 mmol/l or
. venous plasma glucose two hours after ingestion of
75 g oral glucose load (OGTT) = 11.1 mmol/l.
T1DM is primarily due to auto-immune mediated -
cell destruction in the pancreas, often accompanied by
ketoacidosis. There aremanymarkers that can serve as
evidence of this auto-immune process such as islet cell
autoantibodies (ICAs), autoantibodies to insulin (IAAs)
and autoantibodies to glutamic acid decarboxylase
(GAD).4 One or more of these antibodies is present
in 85% to 90%5 of people with T1DM presenting with
fasting hyperglycaemia. Unfortunately there are no
Read codes currently in use record such data.
One biochemical marker that is particularly useful
in the identiﬁcation of T1DM is C-peptide, a by-
product from the conversion of proinsulin to insulin.6
Ketoacidosis is a hallmark of uncontrolled diabetes,
in particular T1DM where deﬁcient insulin results in
cells being starved of glucose and the body providing
an alternative energy source via the metabolism of
amino acids and fatty acids to produce ketones. Despite
an increasing number of ketoacidosis cases now being
reported in Type 2 diabetes (T2DM).7
Clinical characteristics
Young age and absence of obesity are two clinical
characteristics of T1DM and are used by clinicians
to help diﬀerentiate from T2DM. In T1DM polyuria,
polydipsia and weight loss generally arise over a short
period of time compared with T2DM.
T1DM is associated with various other auto-im-
mune diseases such as Crohn’s disease, coeliac disease,
Grave’s disease, Hashimoto’s thyroiditis, Addison’s
disease and pernicious anaemia due to auto-immune
atrophic gastritis. T1DM is present in approximately
5% of ﬁrst-degree relatives,8 transferred predominantly
through themajor histocompatibility complex (MHC).9
Five-byte Read codes are available to indicate the pres-
ence of a family history of diabetes but none are
speciﬁc to T1DM or other types of diabetes.
Therapy
Insulin remains the main treatment for T1DM. Oral
hypoglycaemic drugs are generally not indicated in
T1DM with many now being solely used for the treat-
ment of T2DM. However, the use of metformin
treatment alongside insulin has increased recently as
it has been shown to reduce the daily requirement of
insulin needed to achieve adequate glycaemic con-
trol.10
Type 2 diabetes mellitus (T2DM)
Biochemical markers
Of types of diabetes, T2DM is by far themost common
in the UK with some models suggesting it accounts
for 92%11 of all people with diabetes. Its underlying
pathology is predominantly insulin resistance and
diagnosis is based on plasma glucose using WHO
criteria.
Clinical features
Age and BMI are two of the biggest factors when
considering the likelihood of T2DM. The American
Diabetes Association (ADA) has identiﬁed several risk
factors associated with T2DM which could be used as
potential markers when searching through clinical
records:
. age over 45 years
. BMI more than 30 kg/m2
. family history of diabetes (i.e. parents or siblings
with diabetes)
. race/ethnicity (e.g. Asian/black/Hispanic)
. previously identiﬁed impaired fasting glycaemia (IFG)
or impaired glucose tolerance (IGT)
. history of gestational diabetes mellitus (GDM) or
delivery of a baby weighing more than 4.5 kg
. hypertension (140/90 mmHg in adults)
. polycystic ovary syndrome (PCOS)
. Acanthosis nigricans (AN)
. history of vascular disease.
Therapy
Treatment of T2DM starts with lifestylemodiﬁcations
using diet and exercise; next, with the use of oral hypo-
glycaemic drugs. First line treatment is often with
metformin which can be used in combination with
insulin secretagogues such as sulphonylureas. T2DM
patients do not need insulin for survival, however,
many use it to control their blood glucose levels, often
alongside oral hypoglycaemic drugs.
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Diﬀerentiating between Type 1 and
Type 2 diabetes mellitus
By collating all the diﬀerent characteristics of T1DM
and T2DM, an algorithm for diﬀerentiating between
them was developed:
(i) Determine type of diabetes based on age and
therapy:
. if age<30 AND insulin treated – T1DM prob-
able
. if age>30 AND oral hypoglycaemic treated –
T2DM probable.
(ii) If no therapy is recorded, then patients below 30-
years old should be classed as T1DM unless two
or more of the following markers are present:
. BMI>30 kg/m2 at presentation
. no episodes of ketoacidosis
. black or Asian origin
. presence of AN, PCOS.
(iii) Markers suggestive of T1DM diabetes:
. presentation with polyuria, polydipsia, weight
loss
. these markers aremore signiﬁcant if occurring
over shorter period of time
. presence of other auto-immune diseases.
(iv) Markers suggestive of T2DM diabetes
. presence of serum C-peptides
. anti-obesity drugs.
Single gene type of diabetes
The main type of diabetes falling in this category is
commonly known as maturity onset diabetes of the
young (MODY syndrome). This condition is auto-
somal dominant and can be caused by mutations in
any of six diﬀerent genes expressed in the pancreas
(MODY 1–6). Diagnosis of this type is based on the
WHO criteria and presentation of symptoms is often
mild. Treatment is with insulin and/or oral hypo-
glycaemic drugs but this depends on the exact underlying
mutation. Owing to its relatively low prevalence,
many cases of MODY are initially assumed to be
more common forms of diabetes; T1DM if the
patient is young and not overweight and T2DM
if the patient is overweight. However, MODY can
be screened for by the absence of auto-immune
markers, persistent low requirement of insulin
(e.g. less than 0.5 u/kg/day) and absence of T2DM
risk factors (e.g. obesity, metabolic syndrome etc.).12
Other types of diabetes
Diabetes mellitus can be a secondary consequence of
another underlying pathological process. Diagnosis
of these types is based on the WHO criteria but their
clinical characteristics and treatment are very much
dependent on the underlying pathology. These cases
of diabetes are quite rare in clinical practice making
their detection diﬃcult. One example is diagnosis of
diabetes before six months of age, as less than 1% of
Type 1 diabetes is diagnosed before this age.13
Impaired glucose metabolism
Biochemical markers
Impaired glucose metabolism consists of two pre-
diabetic states, namely impaired fasting glycaemia (IFG)
and impairedglucose tolerance (IGT). It shouldbenoted
that IFG and IGT are not clinical entities in their own
right but rather risk factors for the future development
of diabetes.14 They represent an intermediate stage in
the diabetes disease process where plasma glucose and
OGTT measurements are above normal yet not high
enough to infer diagnosis of diabetes mellitus. IGT
and IFG diagnosis is based on the World Health
Organization criteria summarised in Table 2. These
criteria were used by Shaw et al15 to create an algor-
ithm to diﬀerentiate between IFG, IGT and diabetes as
shown in Figure 1.
Table 2 WHO criteria for the diagnosis of IGT, IFG and diabetes mellitus
Fasting plasma glucose
(mmol/l)
Two hour plasma glucose*
(mmol/l)
Normal 4.0–6.0 AND <7.8
IFG 6.1–6.9 AND <7.8
IGT <6.1 AND 7.8–11.0
Diabetes mellitus =7.0 OR =11.1
*Venous plasma glucose two hours after ingestion of 75 g oral glucose load (OGTT)
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Clinical features
Impaired glucose tolerance often precedes T2DM,
hence metabolic syndrome traits are strongly associ-
ated with it. Other T2DM clinical features are also
relevant, notably age, obesity and Asian ethnic origin.
Therapy
Treatment of IGT is predominantly through lifestyle
modiﬁcation, including both dietary change and
routine exercise. Therapy may include metformin or
antiobesity drugs (though check local drug licensing
arrangements ﬁrst), both of which have been demon-
strated to decrease the risk of Type 2 diabetes
development.16
Gestational diabetes mellitus (GDM)
Gestational diabetes mellitus is deﬁned as glucose
intolerance that appears or is ﬁrst recognised during
pregnancy and disappears after parturition.17Women
with known diabetes who become pregnant do not have
GDM but rather ‘diabetes and pregnancy’ and should
be recorded accordingly during pregnancy. Studies
have shownpatientswithGDMare at an increased risk
of developing Type 2 diabetes in the future.18
Biochemical markers
Despite large amounts of research into GDM there is
still no consensus on its prevalence, diagnosis and
management. In the UK many NHS trusts use the
Scottish Intercollegiate Guideline Network19 criteria
for GDM diagnosis:
. fasting plasma glucose > 5.5 mmol/l or
. two-hour plasma glucose = 9.0 mmol/l.
Glycosuria is unreliable in diagnosingGDMsince 73%20
of pregnant women with glycosuria are not diagnosed
positive for GDM.
Clinical characteristics
Many clinical characteristics and risk factors are
associated with GDM. However, it is important to
assess the strengths of these associations, as the more
relevant ones must have a higher weighting in any
algorithm used to identify women with GDM. The
strong and weak risk factors for GDM are listed below.
Figure 1 Algorithm for the diagnosis of IFG, IGT and diabetes mellitus (adapted from Shaw et al, 2003)
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The strong risk factors:
. age > 30 years20
. family history of diabetes in a ﬁrst degree relative21
. obesity – BMI >30 kg/m2 at booking22
. Asian/black ethnic origin23
. previous history of GDM.24
The weak risk factors:
. previousmacrosomia –>4.5 kg (or >90th centile for
gestational age)25
. previous unexplained stillbirth25
. polyhydramnios26
. large for gestational age (LGA) foetus in current
pregnancy26
. history of PCOS.
Therapy
Treatment of GDM is initially through a regime of diet
and exercise.27 For most patients this is suﬃcient to
control their blood glucose levels and reduce the risk
of complications for bothmother and baby. If diet and
exercise are not successful then insulin therapymay be
considered. The ADA28 has recommended guidance
on the cut-oﬀ values at which insulin should be
initiated:
. fasting plasma glucose > 5.8 mmol/l and
. two-hour plasma glucose > 7.2 mmol/l.
The use of oral hypoglycaemic drugs is not currently
recommended as most of these agents can pass
through the placenta and safety issues have not yet
been fully resolved.28
Algorithm generation and testing
A summary of the ﬁndings are shown inTable 3. There
is potential for non-diagnostic codes to conﬁrm or
refute diagnoses. Exemplar tests have been carried out
and are described below.
The use of plasma glucose levels alone as a non-
diagnostic marker to identify diabetic patients was
speciﬁc and had a high predictive value. The use of
plasma glucose levels greater than 7.0 mmol/l (11.1
mmol/l as per National Institute for Health and
Clinical Excellence (NICE) guidelines) to identify
known diabetic cases had Sn of 48% (17%), speciﬁcity
of 99.5% (99.9%) and PPV of 78% (89.9%). Similarly
the use of HbA1c levels as surrogate markers was stat-
istically robust at identifying cases of pre-diagnosed
diabetics. Levels of HbA1c greater than 6.5 (and 8 as
per WHO guidelines) had an Sn of 73.3% (26%),
speciﬁcity of 99.6% (99%) and PPV of 89% (92%).
The use of a combination of these surrogate
markers in series to generate algorithms for the identi-
ﬁcation of Type 1 and Type 2 diabetics also resulted in
signiﬁcant serial predictive values. The identiﬁcation
of Type 1 diabetics on the basis of an insulin prescrip-
tion and an age under 30 had a positive predictive
value of 84%, and the addition of a BMI of less than
30 kg/m2 resulted in a PPV of 88%. Similarly for Type 2
diabetes use of age greater than 45, BMI greater than
30 kg/m2 and the presence of hypertension gave a PPV
of 30% in identifying previously diagnosed patients.
The addition of the codes for black or Asian race
increased the positive predictive value to 44%.
Discussion
T1DM and T2DM cannot be diﬀerentiated through
blood glucose levels since they are diagnosed accord-
ing to the sameWHO criteria. Auto-immunemarkers
provide evidence of the pancreatic -cell destruction
underlyingT1DM.Unfortunately, these are rarelymeas-
ured in general practice.We therefore used age, therapy,
ethnicity, and obesity to diﬀerentiate between the two
conditions.
The pre-diabetes states, IGT and IFG, are easy to
identify as they have distinct fasting plasma glucose
andOGTT diagnostic criteria (see Figure 1). Gestational
diabetes mellitus is less problematic to identify if
recorded, simply because it can only apply to women
who are pregnant.
Age and therapy are initially used to distinguish
between Type 1 and Type 2 diabetes as they are the
strongest diﬀerential indicators. Other less speciﬁc
markers for distinguishing between T1DM and T2DM
are used in the ﬁnal steps of the algorithm. The success
of using therapy to distinguish between types of
diabetes was mixed. Initial testing of the algorithms
suggest plasma glucose and HbA1c levels have high
speciﬁcity and PPV in identifying diabetic patients.
Implications of ﬁndings
A reﬁned algorithm might identify unrecorded cases
of diabetes and help diﬀerentiate the type of diabetes.
Such algorithms could be used by practices to explore
the gap between their QOF and expected prevalence of
diabetes.
Limitations of the method
Some codes recording blood glucose levels do not
specify whether they relate to fasting, random or
OGTT samples, making electronic patient record
data hard to interpret.
Using surrogate markers in primary electronic patient record systems 127
Table 3 Summary of the biochemistry, clinical features and therapy for the six types of diabetes
Biochemistry Clinical features Therapy
Type 1 Blood glucose levels:
FPG = 7.0 mmol/l OR
two-hour PG = 11.1 mmol/l
Autoimmune antibodies:
ICA, IAA and anti-GAD
positive
C-peptide positive
Ketoacidosis episodes may
be reported
Glycosuria
Young age (<30 years of age)
Acute onset of symptoms
Polyuria, polydipsia, weight
loss
Family history of diabetes
Presence of associated auto-
immune diseases:
Grave’s disease, Hashimoto’s
thyroiditis, Addison’s disease,
Crohn’s disease, coeliac disease
Insulin
Metformin used occasionally
Type 2 Blood glucose levels:
FPG = 7.0 mmol/l OR
two-hour PG = 11.1 mmol/l
Autoimmune antibodies:
ICA, IAA and anti-GAD
negative
C-peptide negative
Ketoacidosis episodes usually
absent
Glycosuria
Older age (>25 years of age)
Obese (BMI >30 kg/m2)
High prevalence in black,
Asian and Hispanic ethnic
groups
Family history of diabetes
Associated conditions:
PCOS, AN
History of IFG, IGT, GDM
Metabolic syndrome
Oral hypoglycaemic drugs:
metformin
insulin secretagogues
thiazolidinediones
Anti-obesity drugs:
Orlistat
Lifestyle changes:
diet, exercise
Insulin used occasionally
Single gene Blood glucose levels:
FPG = 7.0 mmol/l OR
two-hour PG = 11.1 mmol/l
Absence of obesity (BMI
<30 kg/m2)
Absence of metabolic
syndrome traits
Non-black/Asian background
Persistent low requirement of
insulin (<0.5 u/kg/day)
Other Blood glucose levels:
FPG = 7.0 mmol/l OR
two-hour PG =11.1 mmol/l
Autoimmune antibodies
absent
Diagnosis before six months
of age
Insulin
Oral hypoglycaemic drugs
Impaired
glucose
metabolism
Blood glucose levels IGT:
FPG <6.1 mmol/l AND two-
hour PG 7.8–11.1 mmol/l
Blood glucose levels IFP:
FPG 6.1–6.9 mmol/l AND
two-hour PG <7.8 mmol/l
Presence of IFG
Older age (>25 years of age)
Obese (BMI >30 kg/m2)
High prevalence in black,
Asian and Hispanic ethnic
groups
Lifestyle changes:
diet, exercise
Metformin to prevent
development to Type 2
diabetes
GDM Blood glucose levels
FPG 5.5 mmol/l OR
two-hour PG 9.0 mmol/l
Glycosuria
Older age (>30 years of age)
Obese (BMI >30 kg/m2)
High prevalence in black,
Asian and Hispanic ethnic
groups
Family history of diabetes
History of GDM, baby with
macrosomia, stillbirth,
polyhydramnios
Large for gestational age
(LGA) foetus in current
pregnancy
Diet and exercise for most
cases of GDM
Insulin where FPG >5.8
mmol/l AND two-hour
PG >7.2 mmol/l
Oral hypoglycaemic drugs
not recommended due to
possible safety issues
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Another limitation of the algorithms described is
that they treat the various incorporatedmarkers equally.
Other studies investigating screening algorithms have
prioritised diﬀerent markers according to their pre-
dictive value and assigned each marker a clinical score.
The algorithms ignored diagnostic codes, which were
investigated separately.30
Finally, incomplete records make it impossible to
use time sequence analysis (e.g. wasmetformin started
before insulin?) to help distinguish T1DM from T2DM.
Call for further research
The algorithms and criteria presented in this report
could be combined with scoring systems to prioritise
markers, in addition to using a wider range of clinical
data.
Conclusion
Harnessing the power of computerised patient data
provides an opportunity to improve the reporting
of diabetes in primary care. The ambiguity over how
diabetes patients should be classiﬁed has made it
diﬃcult for general practitioners to apply speciﬁc
diagnostic codes to certain cases and has contributed
to the under-reporting of diabetes cases. The use of
non-diagnostic computer codes has the potential to
close the gap between reported cases of diabetes and
the epidemiological prevalence of the disease.
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